Ten Principles for Smarter Regulation
The regulatory landscape is evolving. Growing evidence gives us confidence that more countries will adopt progressive policies. These policies encourage adult smokers, who would otherwise continue to smoke, to switch to reduced-risk*† alternatives and drive a meaningful fall in global smoking prevalence. However, progress depends on collaborative dialogue between policymakers, regulators, public health authorities, and industry. Through mutual understanding, stakeholders can advance Tobacco Harm Reduction while respecting the choices of adult consumers.
Rushed, ideological, or fragmented rules carry unintended consequences. They stifle innovation in reduced-risk*† alternatives and slow the journey toward a smokeless world. This is why we propose ten Smart Regulation principles.
Together they propose a new approach for how policy is developed, debated, and delivered. Each one champions regulation that is clear, enforceable, proportionate, and grounded in science. They call for evidence-led, consultative policymaking rather than reflexive bans.
The principles advocate stakeholder engagement, scientific rigour, enforceability, and long-term stability. Together they build the trust needed for lasting change. They guide consumers toward reduced-risk*† alternatives and encourage responsible innovation. They also deliver measurable outcomes across Clarity, Enforceability, Proportionality, and Public Health Impact. This smarter approach shows BAT’s leadership as a credible, evidence-led partner in making A Smokeless World a regulated reality.
01
Starts with listening.
02
Based on evidence.
03
Practical and clear.
04
Effective not excessive.
05
Easily enforceable.
06
Builds trust.
07
Designed to last.
08
Doesn't backfire.
09
Avoids confusion.
10
Builds confidence.
Footnotes
* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Products sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
Exclusive access to the Omni™ Newsletter
Join the conversation shaping A Better Tomorrow™. Sign up to receive exclusive access to the Omni™ Newsletter and future Omni™ updates.
Signing up to the Omni™ Newsletter does not constitute consent to receive marketing communications.